Table 1.
Patient and tumor characteristics
| Group 1 | Group 2 | |||
|---|---|---|---|---|
| Characteristics | γpCR (n = 21) |
Non-γpCR (n = 75) |
γpCR (n = 9) |
Non-γpCR (n = 34) |
| Sex | ||||
| Male | 14 (18%) | 64 (82%) | 7 (19%) | 29 (81%) |
| Female | 7 (39%) | 11 (61%) | 2 (29%) | 5 (71%) |
| Age (median (IQR)) (years) | 65 (7) | 63 (10) | 65 (6) | 63 (10) |
| Histology | ||||
| Adenocarcinoma | 16 (18%) | 72 (82%) | 8 (%) | 34 (81%) |
| Squamous cell carcinoma | 5 (62%) | 3 (38%) | 1 (100%) | 0 (0%) |
| Tumor location | ||||
| Distal esophagus/GEJ | 21 (22%) | 75 (78%) | 9 (21%) | 34 (79%) |
| Tumor length (median (IQR)) (cm) | 5.0 (5.3) | 6.0 (4.0) | 3.0 (6.5) | 6.0 (4.0) |
| Clinical T-stage | ||||
| T1 and T2 | 6 (55%) | 5 (45%) | 3 (50%) | 3 (50%) |
| T3 and T4a | 15 (18%) | 70 (82%) | 6 (16%) | 31 (84%) |
| Clinical N-stage | ||||
| N0 and N1 | 19 (28%) | 49 (72%) | 8 (27%) | 22 (73%) |
| N2 and N3 | 2 (7%) | 26 (93%) | 1 (8%) | 12 (92%) |
| Number of chemotherapy cycles | ||||
| 4 | 4 (22%) | 14 (78%) | 2 (20%) | 8 (80%) |
| 5 | 17 (22%) | 61 (78%) | 7 (21%) | 26 (79%) |
| Mandard tumor regression grade | ||||
| 1 | 21 (100%) | 0 (0%) | 9 (100%) | 0 (0%) |
| 2 | 0 (0%) | 24 (100%) | 0 (0%) | 12 (100%) |
| 3 | 0 (0%) | 33 (100%) | 0 (0%) | 17 (100%) |
| 4 | 0 (0%) | 16 (100%) | 0 (0%) | 4 (100%) |
| 5 | 0 (0%) | 2 (100%) | 0 (0%) | 1 (100%) |
Abbreviations: γpCR, pathologic complete response; IQR, interquartile range; GEJ, gastroesophageal junction